Talis Biomedical Corporation, a developer of high-performance molecular point-of-care (POC) diagnostic platform to enable physician offices and clinics to run reference lab-quality diagnostic laboratory tests for infectious diseases, received the $4.4 million award from CARB-X.
CARB-X is a non-profit partnership between the UK charity Wellcome Trust, the US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR), and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
The CARB-X award will fund development of a rapid CLIA-waived molecular diagnostic test to detect chlamydia and gonorrhea directly from a patient sample in 20 minutes or less and development of a similarly rapid phenotypic antibiotic susceptibility test for gonorrhea.
Talis’ high-performance, low-cost molecular pathogen identification (ID) system would diagnose chlamydia and gonorrhea from a patient sample in less than 20 minutes. If the diagnosis is positive, the patient would then be tested for antibiotic susceptibility, providing information with 30 minutes about which antibiotics would be most effective to treat gonorrhea. This capability would speed the delivery of appropriate treatment, minimizing unnecessary antibiotic use, and also reduce the epidemiological risk of spreading these diseases.
Since it was established in 2016, CARB-X has announced awards totaling $86.5 million, plus an additional $115.6 million if project milestones are met, to accelerate the development of antibiotics, diagnostics and other products. These funds are in addition to investments made by the companies themselves.